Navigation Links
Wyeth Announces Election of New Principal Corporate Officer
Date:11/15/2007

MADISON, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced that its Board of Directors has elected Andrew F. Davidson as a Principal Corporate Officer effective immediately. Mr. Davidson will continue in his role as Vice President, Internal Audit. He has held several key corporate and divisional financial positions since joining the Company in 1984. These include serving as Vice President - Finance and Chief Financial Officer, Wyeth Consumer Healthcare and Deputy Treasurer, Wyeth.

Prior to joining the Company, Mr. Davidson worked for the public accounting firm of Deloitte, Haskins & Sells. He is a Certified Public Accountant and received a B.B.A. in accounting from Pace University and an M.B.A. in financial management from Iona College.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 Immunovaccine Inc. (“Immunovaccine”) (TSX: ... today announced that the U.S. Food and Drug ... designation and Phase I clinical trials of the ... mutual co-development agreement signed with Gilead Life Sciences. ... for the DPX-Survivac. , “We have been in ...
(Date:2/27/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... with patients and health care advocates in the United ... Day®. Rare Disease Day is dedicated to elevating ... the special challenges faced by patients with rare diseases ... proud to stand alongside patients and caregivers representing the ...
(Date:2/26/2015)... 26, 2015  23andMe, the leading personal genetics company, ... as Privacy Officer and Corporate Counsel. Black brings a ... as well as health care regulations. As a member ... responsible for reviewing, updating and enhancing the company,s privacy ... abroad. She joined the company January 5, 2015 and ...
(Date:2/26/2015)... , Feb. 26, 2015 DuPont Executive ... priorities driven by key research advancements and product launches ... today,s Bank of America Merrill Lynch 2015 Global Agriculture ... challenge of building grain supplies the last two years, ... at the pace of the last decade, when demand ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... (Nasdaq: ONTY ), a biotechnology company specializing in ... of cancer, today announced that it intends to release ... 11, 2009 after market close. Following the release, Oncothyreon,s ... a general business update in a conference call at ...
... PUNE, India, November 2 TeleDiagnosys based ... services has signed up,several new clients from US and ... Teleradiology services to an international clientele in,countries like USA, ... Teleradiology involves transmitting MRI, CT Scan and ...
... Cardium Therapeutics (NYSE Amex: CXM ) today ... the U.S. Food and Drug Administration (FDA) seeking marketing ... Excellagen XL is an advanced wound care management ... designed for use by physicians in patients with topical ...
Cached Biology Technology:MRI & X-Ray Outsourcing Increasing From Hospitals and Imaging Centers Worldwide 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
(Date:2/5/2015)... 2015 Despite a lack of advancements ... as consumer electronics, automotive, storage and telecommunication has ... (SMT) screen printers. Innovations in electronics and conversion ... the adoption curve up. Meanwhile, sale volumes of ... dispensers are indispensable in the production of complex ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... Consumption of foods high in carbohydrates immediately after birth ... University at Buffalo animal study has found, even if caloric ... The research on laboratory animals was published this month ... ; it was published online in December. "This is ...
... Braconidae are known for their deadly reproductive habits. Most ... in other insects and their larvae, eventually killing the respective ... sterility. Three new species of the parasitoid wasp genus ... Hymenoptera Research , reflect this fatal behavior. Two ...
... Trademark Office today awarded St. Jude Children,s Research Hospital ... compositions for genetically modifying human immune cells so they ... cancer in children and adults. "This ... attack certain cells that cause leukemia and lymphoma, cancers ...
Cached Biology News:High-carb intake in infancy has lifelong effects, UB study finds 2High-carb intake in infancy has lifelong effects, UB study finds 3Kill Bill character inspires the name of a new parasitoid wasp species 2St. Jude Children's Research Hospital announces issuance of US patent for cancer therapy 2